Year: 2025

Data published in The New England Journal of Medicine demonstrate RYBREVANT®▼(amivantamab) plus LAZCLUZE®▼ (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5...

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,...

The Global PAD Association has presented the 2025 Walking As Therapy Breakthrough Research of the Year award to The STRIDE Trial Research Team led by Dr. Marc P. Bonaca

Rutgers Robert Wood Johnson Medical School Study Published in JAMA Confirms Butterfly-Enabled POCUS Program Heavily Focused on LUNG US with AI Assistance Reduces Stay and Cost

A QI evaluation of a Butterfly-enabled POCUS program—centered on lung ultrasound for pulmonary congestion and assisted by an AI B-line...

error: Content is protected !!